Intelligent Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes for Enhanced Adoptive Cell Therapy

Publication ID: 24-11857573_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes for Enhanced Adoptive Cell Therapy,” Published Technical Disclosure No. 24-11857573_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857573_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,573.

Summary of the Inventive Concept

This invention integrates AI, IoT, and blockchain technologies with the patented restimulation of cryopreserved tumor infiltrating lymphocytes (TILs) to create a more powerful system for adoptive cell therapy, enabling personalized cancer treatment with improved efficacy and reduced costs.

Background and Problem Solved

The original patent disclosed a method for restimulating cryopreserved TILs for adoptive cell therapy, but it had limitations in terms of scalability, data tracking, and treatment optimization. This new inventive concept addresses these limitations by incorporating advanced technologies to create a more efficient, secure, and effective system.

Detailed Description of the Inventive Concept

The system comprises a blockchain-based data storage module for secure tracking of patient-specific TIL expansion, a machine learning-based predictive analytics module for optimizing restimulation protocols, and an IoT-enabled cell expansion monitoring system for real-time tracking. The system also integrates an AI-driven biomarker analysis module for identifying predictive biomarkers of treatment response and a decentralized blockchain-based platform for secure sharing of patient data. This integrated system enables personalized cancer treatment with improved efficacy, reduced costs, and enhanced patient outcomes.

Novelty and Inventive Step

The new claims introduce the novel combination of AI, IoT, and blockchain technologies with the patented restimulation of cryopreserved TILs, providing a non-obvious solution to the limitations of the original patent. The inventive step lies in the integration of these advanced technologies to create a more powerful system for adoptive cell therapy.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations could also include the integration of additional technologies, such as natural language processing or computer vision, to further enhance the system's capabilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the field of adoptive cell therapy, with potential applications in cancer treatment centers, hospitals, and pharmaceutical companies. The market for adoptive cell therapy is growing rapidly, and this invention could capture a significant share of the market with its enhanced efficacy, reduced costs, and improved patient outcomes.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology, Immunotherapy, and Cell Culture Technologies with a focus on cancer treatment using tumor infiltrating lymphocytes (TILs), requiring advanced knowledge of cell biology, immunology, data science, and medical technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher or engineer with advanced degrees in biomedical engineering, biotechnology, or related fields, possessing expertise in cell culture techniques, machine learning, blockchain technologies, and medical data analysis, with understanding of cancer immunotherapy and personalized medicine approaches

Obviousness Rationale

A person having ordinary skill in the art would recognize that integrating digital technologies like AI, blockchain, and IoT with established TIL restimulation protocols represents a predictable application of known technological solutions to enhance medical research and treatment tracking. The combination of digital monitoring and optimization technologies with existing cell therapy methods would be considered a logical extension of current biotechnological practices. The PTD's proposed variations represent incremental improvements using standard technological integration techniques available to skilled practitioners in the field.

Obvious Combinations & Variations

Source Patent Element

Method of thawing and expanding cryopreserved tumor infiltrating lymphocytes

PTD Variation

Adding machine learning-based predictive analytics for optimizing restimulation protocols

Obviousness Reasoning

Applying machine learning to optimize biological protocols is a known technique in biotechnology, representing a predictable application of data science to existing medical processes

Source Patent Element

Tracking and managing TIL expansion processes

PTD Variation

Implementing blockchain-based data storage for secure patient-specific TIL tracking

Obviousness Reasoning

Using blockchain for secure medical data management is a recognized approach in healthcare informatics, representing a standard technological solution for data integrity and patient privacy

Source Patent Element

Cryopreservation and expansion of tumor infiltrating lymphocytes

PTD Variation

Integrating IoT-enabled real-time cell culture monitoring systems

Obviousness Reasoning

Implementing sensor-based monitoring in cell culture is a predictable technological enhancement, providing continuous data collection using standard IoT technologies

Source Patent Element

Patient-specific TIL expansion methodology

PTD Variation

AI-driven biomarker analysis for predicting treatment response

Obviousness Reasoning

Applying machine learning to genomic data for predictive analysis is a standard approach in personalized medicine, representing an obvious extension of existing diagnostic techniques

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this publication would be considered obvious to a person having ordinary skill in the art at the time of invention, with reference to US Patent 11857573. The integration of digital technologies with established TIL restimulation protocols represents a predictable combination of known techniques in biotechnology and medical informatics, rendering potential claims covering similar technological approaches unpatentable as obvious variations.

Original Patent Information

Patent Number	US 11,857,573
Title	Restimulation of cryopreserved tumor infiltrating lymphocytes
Assignee(s)	Iovance Biotherapeutics, Inc.